Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
GREENWICH, CT – Ria Health (“Ria” or the “Company”), a leading telehealth provider of evidence-based alcohol use disorder (AUD) treatment, today announced the closing of a Series B growth equity round led by Peloton Equity, LLC (“Peloton”), with participation from existing investors including SV Health Investors (“SV”), BPEA Private Equity, and SOSV.
The Company will use the new capital to continue scaling its clinical model and payor coverage, accelerate investments in sales and marketing, and enhance Ria’s differentiated position as a value-add partner in the continuum of AUD care.
Ria delivers AUD treatment nationally, rooted in an evidence-based clinical model that combines medication assisted treatment, behavioral therapy, and coaching. The Company’s industry leading outcomes are driven by a physician-led clinical team and a program designed to meet patients where they are – seeking either harm reduction or abstinence from alcohol. Ria’s focus on the best outcome and experience for the patient, and significant reduction in medical spend for its payor partners, has also led the Company to partner with facility-based AUD providers and AUD-focused digital health companies.
“This investment represents a critical milestone for Ria as we continue to innovate and grow as a leader within AUD treatment,” said Bill Stapleton, CEO of Ria Health. “We are excited to have investor partners that share our vision for a more integrated, evidence-based, and patient-focused continuum of care for alcohol use disorder.”
Ria’s value-based payor arrangements align incentives around improvements in key quality metrics and a phased approach to service utilization. Ria currently has contracts with 15 payors and provides care via telehealth across all 50 states, offering greater patient access and convenience yielding improved clinical outcomes.
With this funding round, Michael O’Rourke, Partner at Peloton Equity, will join Ria Health’s Board of Directors. Ria’s Board of Directors includes Carol Vallone, Chair of the Board of Trustees at McLean Hospital; Dr. Martin Rosenzweig, former Chief Medical Officer (Behavioral) at UnitedHealthGroup; Michael Balmuth, Managing Partner at SV; Dr. John Mendelson, founder and Chief Medical Officer of Ria; and Bill Stapleton, CEO of Ria.
“Ria’s business model and AUD-focused clinical program produce unparalleled access to specialized, cost-effective treatment and incredible patient outcomes,” said Michael O’Rourke. “The Company has already demonstrated strong momentum on the path to transforming the AUD treatment industry, and we look forward to supporting its continued innovation and growth.”
About Ria Health
Over their lifetime, 1 in 10 adults will struggle with alcohol use disorder, the third-leading cause of preventable death in the United States. At Ria Health, we envision a world with accessible, effective, and compassionate treatment for people who suffer from alcohol misuse. Ria Health is the first evidence-based telehealth treatment program for people who want to drink less and live better by changing their relationship with alcohol. We combine medical science, technology, and human compassion to help people rapidly improve their lives with a simple, online alcohol treatment program that works. For more information, visit riahealth.com.
About Peloton Equity
Peloton Equity, LLC (pelotonequity.com) is a private equity firm focused exclusively on growth capital investments in the healthcare industry. Peloton was formed in 2014 as the successor firm to Ferrer Freeman & Company (“FFC”) and invests in companies with between $10 million and $200 million of revenue that have the management team, market opportunity and business model to become category leaders. Peloton’s investment team has invested in over 36 unique healthcare companies and has deployed over $900 million in capital.
About SV Health Investors
SV Health Investors (svhealthinvestors.com) is a private equity firm dedicated to investments in the healthcare and life sciences sector. Founded in 1993 with offices in Boston and London, SV manages approximately $2.0 billion across multiple investment strategies. SV's dedicated healthcare Growth-Buyout strategy seeks to partner with experienced management teams to accelerate the success of innovative healthcare companies across healthcare SV combines decades of healthcare transaction and operating experience to drive long-term value creation and realize the triple aim of healthcare – higher quality care, accessible to more patients, at a lower cost.
About BPEA
Established in 2002, BPEA (www.bpea-pe.com) is a Boston-based private equity firm focused on small and lower middle market buyout and growth investing, and customized investment solutions to meet investors’ private equity goals. BPEA offers dedicated small market buyout and growth investment programs as well as dedicated strategic healthcare-focused programs and invests in fund managers and directly in companies. Since inception, BPEA has made buyout and growth investments in over 125 funds and 190 companies.